Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 484

1.

Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.

Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM.

Arch Neurol. 2008 Sep;65(9):1231-6. doi: 10.1001/archneurol.2008.1.

PMID:
18779428
[PubMed - indexed for MEDLINE]
2.

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.

Arch Neurol. 2007 Sep;64(9):1306-11.

PMID:
17846270
[PubMed - indexed for MEDLINE]
3.

Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.

Ercoli L, Siddarth P, Huang SC, Miller K, Bookheimer SY, Wright BC, Phelps ME, Small G.

Arch Gen Psychiatry. 2006 Apr;63(4):442-8.

PMID:
16585474
[PubMed - indexed for MEDLINE]
4.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
[PubMed - indexed for MEDLINE]
5.

Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly.

Dik MG, Jonker C, Comijs HC, Bouter LM, Twisk JW, van Kamp GJ, Deeg DJ.

Neurology. 2001 Dec 26;57(12):2217-22.

PMID:
11756600
[PubMed - indexed for MEDLINE]
6.

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.

Arch Neurol. 2005 Jun;62(6):975-80.

PMID:
15956169
[PubMed - indexed for MEDLINE]
7.

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.

Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH.

Arch Neurol. 2003 Oct;60(10):1394-9.

PMID:
14568809
[PubMed - indexed for MEDLINE]
8.

Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG.

Neurology. 2004 Jun 8;62(11):1990-5.

PMID:
15184602
[PubMed - indexed for MEDLINE]
9.

Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: A population-based study.

Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C.

Stroke. 2000 Oct;31(10):2431-6.

PMID:
11022076
[PubMed - indexed for MEDLINE]
Free Article
10.

Principal component analysis of FDG PET in amnestic MCI.

Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, Dessi B, Larsson SA, Rodriguez G, Pagani M.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2191-202. doi: 10.1007/s00259-008-0869-z. Epub 2008 Jul 22.

PMID:
18648805
[PubMed - indexed for MEDLINE]
11.

Neuropsychological measures in normal individuals that predict subsequent cognitive decline.

Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M.

Arch Neurol. 2007 Jun;64(6):862-71.

PMID:
17562935
[PubMed - indexed for MEDLINE]
12.

FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.

Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B.

Neurocase. 2005 Feb;11(1):14-25.

PMID:
15804920
[PubMed - indexed for MEDLINE]
13.

Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.

Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K.

J Alzheimers Dis. 2011;25(4):695-706. doi: 10.3233/JAD-2011-100996.

PMID:
21498904
[PubMed - indexed for MEDLINE]
14.

Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study.

Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, Caroli A, Frisoni G, Rodriguez G, Nobili F.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):36-45. doi: 10.1007/s00259-009-1218-6. Epub .

PMID:
19662411
[PubMed - indexed for MEDLINE]
15.

Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.

Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D, Alexander GE, Burns CM, Kaszniak AW, Reeder SA, Corneveaux JJ, Allen AN, Pruzin J, Huentelman MJ, Fleisher AS, Reiman EM.

Arch Neurol. 2010 Apr;67(4):462-8. doi: 10.1001/archneurol.2010.30.

PMID:
20385913
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.

Pomara N, Willoughby L, Wesnes K, Greenblatt DJ, Sidtis JJ.

Arch Gen Psychiatry. 2005 Feb;62(2):209-16.

PMID:
15699298
[PubMed - indexed for MEDLINE]
17.

APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.

Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ.

Neurology. 2000 Apr 11;54(7):1492-7.

PMID:
10751265
[PubMed - indexed for MEDLINE]
18.

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study.

Arch Neurol. 2004 Jan;61(1):59-66.

PMID:
14732621
[PubMed - indexed for MEDLINE]
19.

Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.

Chételat G, Landeau B, Eustache F, Mézenge F, Viader F, de la Sayette V, Desgranges B, Baron JC.

Neuroimage. 2005 Oct 1;27(4):934-46.

PMID:
15979341
[PubMed - indexed for MEDLINE]
20.

Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.

Stonnington CM, Snyder PJ, Hentz JG, Reiman EM, Caselli RJ.

J Clin Psychiatry. 2009 Oct;70(10):1379-84. doi: 10.4088/JCP.08m04593. Epub 2009 Jun 30.

PMID:
19573495
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk